Asianet Newsable on MSN
CMPS stock defies market selloff after Compass Pathways psilocybin trial success pointing to 2027 launch
Compass said patients who received an additional 25 mg dose of COMP360 saw their depression scores improve by an average of ...
Compass Pathways (NASDAQ:CMPS) climbed 4% on Wednesday after new 52-week data from the company's Phase III study of COMP360, its investigational oral psilocybin treatment for treatment-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results